Published in J Clin Microbiol on October 01, 2008
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob Agents Chemother (2009) 0.90
Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections. Clin Microbiol Rev (2016) 0.89
Thymidine auxotrophic Staphylococcus aureus small-colony variant endocarditis and left ventricular assist device infection. J Clin Microbiol (2012) 0.84
Structure of S. aureus HPPK and the discovery of a new substrate site inhibitor. PLoS One (2012) 0.79
Optimized In Vitro Antibiotic Susceptibility Testing Method for Small-Colony Variant Staphylococcus aureus. Antimicrob Agents Chemother (2016) 0.79
Thymidine-Dependent Staphylococcus aureus Small-Colony Variants Are Induced by Trimethoprim-Sulfamethoxazole (SXT) and Have Increased Fitness during SXT Challenge. Antimicrob Agents Chemother (2015) 0.79
Synergistic antimicrobial activities of folic acid antagonists and nucleoside analogs. Antimicrob Agents Chemother (2009) 0.78
Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model. Antimicrob Agents Chemother (2009) 0.75
The identification of Staphylococcus aureus factors required for pathogenicity and growth in human blood. Infect Immun (2017) 0.75
Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol (2006) 5.73
Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis (1998) 3.61
Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis (1995) 3.49
Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with darier's disease. Clin Infect Dis (2001) 2.14
Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phenotypes. Infect Immun (2002) 2.08
Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. J Clin Microbiol (1987) 1.80
Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis (2008) 1.78
Thymidine-dependent small-colony variants of Staphylococcus aureus exhibit gross morphological and ultrastructural changes consistent with impaired cell separation. J Clin Microbiol (2003) 1.71
Recurrent ventriculoperitoneal shunt infection caused by small-colony variants of Staphylococcus aureus. Clin Infect Dis (2005) 1.53
Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem (2001) 1.52
Fatal case due to methicillin-resistant Staphylococcus aureus small colony variants in an AIDS patient. Emerg Infect Dis (1999) 1.48
Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol (2006) 1.45
Bloodstream infections caused by small-colony variants of coagulase-negative staphylococci following pacemaker implantation. Clin Infect Dis (1999) 1.39
Thymidine-dependent Staphylococcus aureus small-colony variants are associated with extensive alterations in regulator and virulence gene expression profiles. Infect Immun (2005) 1.35
Molecular analysis of the thymidine-auxotrophic small colony variant phenotype of Staphylococcus aureus. Int J Med Microbiol (2007) 1.29
In vivo mutations of thymidylate synthase (encoded by thyA) are responsible for thymidine dependency in clinical small-colony variants of Staphylococcus aureus. J Bacteriol (2007) 1.27
The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother (2008) 1.26
Transcription of virulence factors in Staphylococcus aureus small-colony variants isolated from cystic fibrosis patients is influenced by SigB. J Bacteriol (2006) 1.20
Clonal heterogeneity, distribution, and pathogenicity of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1997) 1.13
Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus. Infect Immun (2007) 0.97
Thymidine concentrations in human sera: variations in patients with leukaemia and megaloblastic anaemia. Eur J Cancer (1980) 0.94
Radioimmunoassays of plasma thymidine, uridine, deoxyuridine, and cytidine/deoxycytidine. Anal Biochem (1981) 0.84
Quality evaluation of Cordyceps through simultaneous determination of eleven nucleosides and bases by RP-HPLC. J Sep Sci (2006) 0.83
A multiplex real-time PCR assay for rapid detection and differentiation of 25 bacterial and fungal pathogens from whole blood samples. Med Microbiol Immunol (2007) 2.64
Host association of Borrelia burgdorferi sensu lato--the key role of host complement. Trends Microbiol (2002) 2.47
NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother (2011) 2.40
Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. J Antimicrob Chemother (2011) 2.26
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.79
The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Dtsch Arztebl Int (2016) 1.77
Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol (2003) 1.76
Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy. Gastroenterology (2005) 1.59
Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June‒December 2015. Euro Surveill (2016) 1.54
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother (2008) 1.51
Improved detection of blood stream pathogens by real-time PCR in severe sepsis. Intensive Care Med (2009) 1.51
Immune evasion of Borrelia burgdorferi: mapping of a complement-inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. Eur J Immunol (2003) 1.45
Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol (2006) 1.45
Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol Microbiol (2006) 1.43
Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-β-lactamase with increased carbapenemase activity. J Antimicrob Chemother (2013) 1.42
Zoonotic babesiosis: overview of the disease and novel aspects of pathogen identity. Ticks Tick Borne Dis (2009) 1.42
Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials (2005) 1.41
Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int J Antimicrob Agents (2004) 1.33
Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany. J Clin Microbiol (2002) 1.29
Potential clinical utility of polymerase chain reaction in microbiological testing for sepsis. Crit Care Med (2009) 1.29
Molecular analysis of the thymidine-auxotrophic small colony variant phenotype of Staphylococcus aureus. Int J Med Microbiol (2007) 1.29
First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen. Int J Med Microbiol (2007) 1.28
Identification and functional characterization of complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes Borrelia afzelii and Borrelia garinii. Infect Immun (2005) 1.27
The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother (2008) 1.26
Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect Dis (2010) 1.24
Coordinated expression of Borrelia burgdorferi complement regulator-acquiring surface proteins during the Lyme disease spirochete's mammal-tick infection cycle. Infect Immun (2007) 1.18
Immunological characterization of the complement regulator factor H-binding CRASP and Erp proteins of Borrelia burgdorferi. Int J Med Microbiol (2004) 1.18
Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis (2007) 1.17
Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the german infection serology proficiency testing program. J Clin Microbiol (2006) 1.17
Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch (2007) 1.14
Integrated detection of extended-spectrum-beta-lactam resistance by DNA microarray-based genotyping of TEM, SHV, and CTX-M genes. J Clin Microbiol (2009) 1.12
Individual cases of autochthonous malaria in Evros Province, northern Greece: serological aspects. Parasitol Res (2002) 1.06
A novel fold for the factor H-binding protein BbCRASP-1 of Borrelia burgdorferi. Nat Struct Mol Biol (2005) 1.04
Human pathogenic Borrelia spielmanii sp. nov. resists complement-mediated killing by direct binding of immune regulators factor H and factor H-like protein 1. Infect Immun (2007) 1.04
Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2005) 1.04
Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology. Dtsch Arztebl Int (2012) 1.03
Quality of Lyme disease serology. Lessons from the German Proficiency Testing Program 1999-2001. A preliminary report. Wien Klin Wochenschr (2002) 1.03
Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care (2014) 1.02
Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): Expression patterns during the mammal-tick infection cycle. Int J Med Microbiol (2007) 0.99
Surface-associated motility, a common trait of clinical isolates of Acinetobacter baumannii, depends on 1,3-diaminopropane. Int J Med Microbiol (2012) 0.98
Borrelia burgdorferi regulates expression of complement regulator-acquiring surface protein 1 during the mammal-tick infection cycle. Infect Immun (2005) 0.98
Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus. Infect Immun (2007) 0.97
Multidrug-resistant bacteria in geriatric clinics, nursing homes, and ambulant care--prevalence and risk factors. Int J Med Microbiol (2013) 0.96
Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know. Wien Klin Wochenschr (2006) 0.95
Complement regulator-acquiring surface proteins of Borrelia burgdorferi: a new protein family involved in complement resistance. Wien Klin Wochenschr (2002) 0.92
Deciphering the ligand-binding sites in the Borrelia burgdorferi complement regulator-acquiring surface protein 2 required for interactions with the human immune regulators factor H and factor H-like protein 1. J Biol Chem (2008) 0.92
Serologic evidence for effective production of cytolysin A in Salmonella enterica serovars typhi and paratyphi A during human infection. Infect Immun (2006) 0.92
The borrelial fibronectin-binding protein RevA is an early antigen of human Lyme disease. Clin Vaccine Immunol (2009) 0.91
Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Transl Stroke Med (2011) 0.91
Immune evasion of Borrelia burgdorferi: insufficient killing of the pathogens by complement and antibody. Int J Med Microbiol (2002) 0.90
Early production of IL-22 but not IL-17 by peripheral blood mononuclear cells exposed to live Borrelia burgdorferi: the role of monocytes and interleukin-1. PLoS Pathog (2010) 0.90
Binding of human complement regulators FHL-1 and factor H to CRASP-1 orthologs of Borrelia burgdorferi. Wien Klin Wochenschr (2006) 0.89
Borrelia burgdorferi complement regulator-acquiring surface protein 2 (CspZ) as a serological marker of human Lyme disease. Clin Vaccine Immunol (2007) 0.88
Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000. Clin Chem Lab Med (2015) 0.88
Mutational analyses of the BbCRASP-1 protein of Borrelia burgdorferi identify residues relevant for the architecture and binding of host complement regulators FHL-1 and factor H. Int J Med Microbiol (2009) 0.87
Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents--possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol (2002) 0.87
[Flap Amputation in Mycobacterium chelonae Keratitis after Laser-in-situ Keratomileusis (LASIK)]. Klin Monbl Augenheilkd (2003) 0.86
Proline metabolism in the moderately halophilic bacterium Halobacillus halophilus: differential regulation of isogenes in proline utilization. Environ Microbiol Rep (2010) 0.86
Eosinophilic meningitis due to Angiostrongylus cantonensis in Germany. J Travel Med (2009) 0.86
Development and laboratory evaluation of a new recombinant ELISA for the serodiagnosis of Lyme disease. Wien Klin Wochenschr (2002) 0.85
Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi. Ticks Tick Borne Dis (2010) 0.85
In vitro activity of eight oral cephalosporins against Borrelia burgdorferi. Int J Antimicrob Agents (2003) 0.84
Mixed diarrhoeal infection caused by Vibrio cholerae and several other enteric pathogens in a 4-year-old child returning to Germany from Pakistan. Scand J Infect Dis (2005) 0.84
Structure-function mapping of BbCRASP-1, the key complement factor H and FHL-1 binding protein of Borrelia burgdorferi. Int J Med Microbiol (2006) 0.84
Synthesis of glycine betaine from choline in the moderate halophile Halobacillus halophilus: co-regulation of two divergent, polycistronic operons. Environ Microbiol Rep (2009) 0.84
Quantification of vancomycin in human serum by LC-MS/MS. Clin Chem Lab Med (2013) 0.83
Systematic analysis highlights the key role of TLR2/NF-kappaB/MAP kinase signaling for IL-8 induction by macrophage-like THP-1 cells under influence of Borrelia burgdorferi lysates. Int J Biochem Cell Biol (2008) 0.83
Primary intestinal aspergillosis after high-dose chemotherapy and autologous stem cell rescue. Pediatr Infect Dis J (2006) 0.82
Identification and characterization of the factor H and FHL-1 binding complement regulator-acquiring surface protein 1 of the Lyme disease spirochete Borrelia spielmanii sp. nov. Int J Med Microbiol (2008) 0.82
Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother (2004) 0.82
Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes. J Dtsch Dermatol Ges (2011) 0.81
Cecal ligation and incision: an acute onset model of severe sepsis in rats. J Surg Res (2008) 0.81
Autoinducer-2-producing protein LuxS, a novel salt- and chloride-induced protein in the moderately halophilic bacterium Halobacillus halophilus. Appl Environ Microbiol (2006) 0.81
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res (2012) 0.81
Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization. Clin Chem Lab Med (2014) 0.79
New real-time PCR-based method for in vitro susceptibility testing of Anaplasma phagocytophilum against antimicrobial agents. Int J Antimicrob Agents (2004) 0.78
Generation and characterization of anti-Candida T cells as potential immunotherapy in patients with Candida infection after allogeneic hematopoietic stem-cell transplant. J Infect Dis (2007) 0.78
Release of latent ClyA cytolysin from Escherichia coli mediated by a bacteriophage-associated putative holin (BlyA) from Borrelia burgdorferi. Int J Med Microbiol (2007) 0.78
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation. Clin Chem Lab Med (2015) 0.78
Synergistic antimicrobial activities of folic acid antagonists and nucleoside analogs. Antimicrob Agents Chemother (2009) 0.78
Novel promising linezolid analogues: rational design, synthesis and biological evaluation. Eur J Med Chem (2013) 0.77